🚀 VC round data is live in beta, check it out!
Cessatech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cessatech and similar public comparables like Telomir Pharmaceuticals, Nicox, Xilio Therapeutics, Rein Therapeutics and more.
Cessatech Overview
About Cessatech
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. Its product (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. Its other products CT002 which is a Non-invasive nasal spray and CT003 which is a local anaesthetic gel are in different stages development.
Founded
2020
HQ
Employees
4
Website
Sectors
Financials (FY)
EV
$48M
Cessatech Financials
Cessatech reported last fiscal year revenue of $901K and negative EBITDA of ($2M).
In the same fiscal year, Cessatech generated ($2M) in EBITDA losses and had net loss of ($2M).
Cessatech P&L
In the most recent fiscal year, Cessatech reported revenue of $901K and EBITDA of ($2M).
Cessatech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $901K | XXX | XXX | XXX |
| EBITDA | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (262%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (262%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (191%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cessatech Stock Performance
Cessatech has current market cap of $50M, and enterprise value of $48M.
Market Cap Evolution
Cessatech's stock price is $2.68.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $48M | $50M | 0.7% | XXX | XXX | XXX | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCessatech Valuation Multiples
Cessatech trades at 53.7x EV/Revenue multiple, and (20.5x) EV/EBITDA.
Cessatech Financial Valuation Multiples
As of April 18, 2026, Cessatech has market cap of $50M and EV of $48M.
Equity research analysts estimate Cessatech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cessatech has a P/E ratio of (29.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50M | XXX | $50M | XXX | XXX | XXX |
| EV (current) | $48M | XXX | $48M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 53.7x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (20.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (20.5x) | XXX | XXX | XXX |
| P/E | — | XXX | (29.0x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (17.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cessatech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cessatech Margins & Growth Rates
Cessatech's revenue in the last fiscal year grew by 130%.
Cessatech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.8M for the same period.
Cessatech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 130% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (262%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (21%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 362% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cessatech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Telomir Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Nicox | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Rein Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cessatech M&A Activity
Cessatech acquired XXX companies to date.
Last acquisition by Cessatech was on XXXXXXXX, XXXXX. Cessatech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cessatech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCessatech Investment Activity
Cessatech invested in XXX companies to date.
Cessatech made its latest investment on XXXXXXXX, XXXXX. Cessatech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cessatech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cessatech
| When was Cessatech founded? | Cessatech was founded in 2020. |
| Where is Cessatech headquartered? | Cessatech is headquartered in Denmark. |
| How many employees does Cessatech have? | As of today, Cessatech has over 4 employees. |
| Is Cessatech publicly listed? | Yes, Cessatech is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Cessatech? | Cessatech trades under CESSA ticker. |
| When did Cessatech go public? | Cessatech went public in 2020. |
| Who are competitors of Cessatech? | Cessatech main competitors are Telomir Pharmaceuticals, Nicox, Xilio Therapeutics, Rein Therapeutics. |
| What is the current market cap of Cessatech? | Cessatech's current market cap is $50M. |
| What is the current revenue of Cessatech? | Cessatech's last fiscal year revenue is $901K. |
| What is the current EV/Revenue multiple of Cessatech? | Current revenue multiple of Cessatech is 53.7x. |
| Is Cessatech profitable? | No, Cessatech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.